Digest Network Come funziona
Network
/
Società
Ev
Non verificato

Evaxion

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaManagement/Organizzazione AziendalePubblicità/Marketing/Media/Comunicazione

42 comunicati stampa

Guarda tutti i comunicati
17/07/2026
Biotecnologia
Annunci Economici
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
12/07/2026
Biotecnologia
Annunci Economici
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
01/07/2026
Biotecnologia
Annunci Economici
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
12/06/2026
Biotecnologia
Annunci Economici
Evaxion receives Prix Galien UK Award for Best digital health solution
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Biotecnologia
Annunci Economici
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
12/05/2026
Biotecnologia
Annunci Economici
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
07/05/2026
Biotecnologia
Annunci Economici
Management/Organizzazione Aziendale
Evaxion announces business update and first quarter 2026 financial results
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
04/05/2026
Biotecnologia
Annunci Economici
Management/Organizzazione Aziendale
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
27/04/2026
Biotecnologia
Annunci Economici
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0
17/04/2026
Biotecnologia
Annunci Economici
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Fonte
Evaxion
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0